Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Joint Seminar on Global Biocompatibility (US) September 1995:

This article was originally published in Clinica

Executive Summary

Two testing laboratories, NAmSA (US) and TUV Product Service (Germany) are holding a joint seminar on Global Biocompatibility on September 15th, 1995, in Lexington, MA, US. It is aimed at those involved in quality assurance, regulatory affairs, product development and international business management. Further information is available from: Mary Thornton, Marketing Co-ordinator, NAmSA, 2261 Tracy Road, Northwood, OH 43619, US. Tel: +1 (419) 666 9455. Fax: +1 (419) 666 2954.

You may also be interested in...



Cosmetics Weekly Trademark Review: 10 December 2019

Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps.

Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players

Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.

Finland's Forendo Attracts Big Pharma For Liver Disease R&D

Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.


 

Topics

UsernamePublicRestriction

Register

MT091712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel